Bringing the first of a new class of medicines to market was only the beginning of RNAi’s journey. Building on Alnylam’s pioneering work, the Futurists are identifying new targets for RNAi therapeutics beyond the liver and orphan diseases and are leveraging the company’s investment in genomics and data sciences to accelerate drug development. Through their efforts, the Futurists are expanding the role that RNAi-based medicines can play in treating human disease.